- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04620031
A Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Mechanical Ventilation
A Multi-Center, Randomized, Single-Blind, Propofol-Controlled Phase III Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Mechanical Ventilation
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Guangzhou, Cina
- The First Affiliated Hospital of Sun Yat-sen University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients who require tracheal intubation for mechanical ventilation are expected to require 6-24 h of sedation after randomization;
- The target RASS for the required sedation of patients ranges from +1 to -2 points;
- Aged ≥ 18 and < 80 years old, with no gender requirement;
- 18 kg/m2 ≤ BMI ≤ 30 kg/m2;
- The patients or their family members fully understand the objectives and significance of this study, and voluntarily participate in this clinical study and sign the informed consent form.
Exclusion Criteria:
- Patients known to be allergic to eggs, soy products, opioids and their antidotes, and propofol; patient having contraindications to propofol, opioids and their antidotes;
- Patients who have received sedation for more than 3 days in the ICU or in the general ward before being transferred to the ICU before signing informed consent form;
Patients having the following medical history or evidence of any of the following at screening, which may increase sedation/anesthesia risk:
- Cardiovascular system: New York Heart Association (NYHA) Class III and IV heart failure, Adams-stokes syndrome; acute coronary syndrome (ACS) that occurs within 6 months before screening; bradycardia requiring medication and/or heart rate ≤ 50 beats/min; a history of severe arrhythmia such as II-III degree atrioventricular block (excluding patients using pacemakers); acute and chronic myocarditis; patients who require vasoactive drugs to maintain a normal blood pressure;
- Patients with mental system disorders (such as schizophrenia, depression, etc.) and cognitive disorders; patients with a history of abuse of psychotropic drugs and anesthetics; patients with a history of alcohol abuse within 3 months prior to screening; patients with a history of drug abuse; patients with a history of long-term use of psychotropic drugs, etc.;
- Severe hepatic and renal insufficiency (liver function: refer to child-pugh grade C, the scale is shown in Appendix 6; renal function: glomerular filtration rate eGFR ≤ 30 mL/(min•1.73 m2) [eGFR is calculated using the Modification of Diet in Renal Disease (MDRD) equation: eGFR = 175 × serum creatinine (SCr)-1.234 × age-0.179 × 0.79 (females)]; patients undergoing dialysis;
- Grand mal epilepsy and convulsion; craniocerebral injury, intracranial hypertension, cerebral aneurysm; a Glasgow coma scale (GCS) of ≤ 12 points (see Appendix 4 for the scale); a SOFA scale of > 9 points (see Appendix 5 for the scale); patients with high paraplegia and general paralysis;
- Expected survival of ≤ 72 h.
- Pregnant or lactating females; women or men of child-bearing potential who are unwilling to use contraception through the study; subjects who are planning pregnancy within 1 month after the study (including male subjects);
- Have participated in any other clinical trials within 1 month prior to screening;
- Other conditions that patients are judged by the investigator to be unsuitable for participating in the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: HSK3486
HSK3486 per la sedazione
|
Loading Dose:0.1 mg/kg, infused with 4 min ± 30 s; Maintenance Dose:Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h.
Range of maintenance dose: 0.06-0.8
mg/kg/h
|
|
Comparatore attivo: Propofol
Propofol per la sedazione
|
Loading Dose:0.5 mg/kg, infused with 4 min ± 30 s Maintenance Dose:Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose: 0.3-4 mg/kg/h |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Success rate of sedation
Lasso di tempo: Within 24 hours of administration
|
1) The time period during which the RASS is in the range of +1 to -2 accounts for ≥ 70% of the total duration of study administration and 2) Remedial treatment is not used.
|
Within 24 hours of administration
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Tempo di estubazione
Lasso di tempo: Entro 24 ore dalla somministrazione
|
il tempo dall'intubazione (applicabile ai pazienti sottoposti a intubazione dopo l'ingresso in terapia intensiva)/ricovero in terapia intensiva (applicabile ai pazienti con intubazione prima dell'ingresso in terapia intensiva) all'estubazione o il tempo dall'interruzione del farmaco all'estubazione
|
Entro 24 ore dalla somministrazione
|
|
Mean qualified rate of sedation
Lasso di tempo: Within 24 hours of administration
|
Defined as the percentage of time period during which the RASS is in the range of +1 to -2 relative to the total duration of study administration
|
Within 24 hours of administration
|
|
Use of study drug
Lasso di tempo: Within 24 hours of administration
|
the loading doses of HSK3486 and propofol, mean maintenance dose and total dose per unit weight per hour of HSK3486 or propofol, and the number of dose modifications and the number of top up doses during the maintenance period
|
Within 24 hours of administration
|
|
Dose of remedial drugs per unit weight
Lasso di tempo: Within 24 hours of administration
|
the mean dose per unit weight per hour of other sedatives used to maintain the target sedation (RASS within +1 to -2 points)
|
Within 24 hours of administration
|
|
Time to recovery
Lasso di tempo: Within 24 hours after administration
|
the time for the subject to recover from sedation to full recovery of consciousness (RASS ≥ 0) after discontinuation of drug administration
|
Within 24 hours after administration
|
|
Incidence of adverse events
Lasso di tempo: From day -1 to 24 hours after administration
|
safety endpoits
|
From day -1 to 24 hours after administration
|
Collaboratori e investigatori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- HSK3486-307
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .